Nereus Pharmaceuticals, Inc.
2 clinical trials · Sponsor
◉ Watch Nereus Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer (NCT00630110) | Nereus Pharmaceuticals, Inc. | 2008-02-01 |
| Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma (NCT00322608) | Nereus Pharmaceuticals, Inc. | 2006-04-01 |
Track Nereus Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.